PFM
BMRN icon

Privium Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Privium Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.29M Sell
75,000
-17,305
-19% -$948K 0.79% 25
2026
Q1 		$5.21M Buy
+92,305
New +$5.38M 1.09% 22

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Privium Fund Management's BMRN Position: Q2 2026 in Review

Privium Fund Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 19% in Q2 2026, selling an estimated $948K and leaving 75,000 shares worth $4.29M. The position accounts for 0.79% of the portfolio, ranked #25.

Privium Fund Management first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.21M in Q1 2026. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Privium Fund Management held 75,000 shares of BioMarin Pharmaceuticals worth $4.29M as of Q2 2026.
  • Privium Fund Management sold 17,305 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $948K.
  • BioMarin Pharmaceuticals made up 0.79% of Privium Fund Management's portfolio in Q2 2026, its #25 holding.
  • Privium Fund Management first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Privium Fund Management's BioMarin Pharmaceuticals position peaked at $5.21M in Q1 2026.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.